

Curriculum vitae

PERSONAL INFORMATION

Name: Olga

Cognome: Mulas

Date of birth: 17/05/1987

Place of birth: Lanusei (Nu)

Nationality: Italian

Recapito Mail: mulasolga@unica.it, mulasolga@gmail.com

RECAPITO PEC: olga.mulas@pec.omeca.it

ACADEMIC QUALIFICATIONS AND PROFESSIONAL PROFILE

02/11/2024 to today

Associate Professor at the University of Cagliari, (SSD MEDS-09/B, Blood Diseases) Department of Medical Sciences and Public Health.

18/03/2020 to today

Consultant in Ematologia-Centro Trapianti Midollo Osseo, Azienda Ospedaliera Brotzu, Businco Hospital, Via Jenner s.n., 09121 Cagliari, Italy

02/11/2021 to 01/11/2024

Hematology Researcher, department of medical sciences and public health, University of Cagliari (RTDB)

02/12/2019 to 01/11/2021

Hematology Researcher, department of medical sciences and public health, University of Cagliari (RTDA)

23/04/2019 to 28/11/2019

Recipient of a two-year research grant at the University of Cagliari entitled "Modulation of interferon-gamma production and role in cell lines derived from lymphomas/leukemias"

Dal 13/11/2018 al 12/02/2019

Independent professional work assignment for "Clinical management and data management of experimental protocols related to myeloproliferative pathologies within the research projects of the Haematology Research Unit"

14/09/2018 to 06/04/2019

Attività di libero professionista nella disciplina di Ematologia con ambulatorio in convenzione con il Sistema sanitario nazionale presso la Casa di Cura Tommasini di Jerzu

10/08/2018

Specialization in Haematology with a 50/50 vote and honors, with the thesis titled "Evaluation in Clinical Practice of Cardiovascular Toxicity in Patients Suffering from Chronic Myeloid Leukemia Treated with Second-Generation Tyrosine Kinase Inhibitors: Identification of Risk Factors and Role of Prophylaxis." Graduate School of Hematology, University of Sassari and University of Cagliari

23/10/2012

Degree in Medicine and Surgery with a score of 110/110 and honors for the thesis entitled "Role of Natural Killer Cells and KIR Receptors in the Pathogenesis and Therapeutic Response of Chronic Myeloid Leukemia," University of Cagliari.

TEACHING ACTIVITY

2023- today Teaching assignment of Haematology - module of [mc/0876] clinical pathology and immunoematology in the degree course: Biomedical Laboratory Techniques (enabling to the health profession of biomedical laboratory technician)

2020- today

Teaching assignment of Hematology (MED 15) in the course of Ematology Degree Course Medicine and Surgery

2020- today

Teaching assignment in Hematology at the Graduate School of Hematology, University of Cagliari

2021- today

Teaching assignment in Hematology at the Graduate School of Medical Genetic, University of Cagliari

2020- today

Lecturer and co-author of several theses for the undergraduate program in Medicine and Surgery at the University of Cagliari

2020- today

Member of the Coordinating Committee of the Graduate School of Haematology

29-04-2023 today

Member of the Faculty of the PhD accredited by the Ministry, entitled "MOLECULAR AND TRANSLATIONAL MEDICINE" - DOT1404000, University of Cagliari

RESEARCH ACTIVITIES

Research areas of preference

Chronic myeloproliferative syndromes

Non-oncological haematological diseases

Rare diseases

Role of target therapy in the incidence of cardiovascular events

Quality of life in haematological diseases

2019-today

Junior member of EHA (European Hematology Association)

2018- today

SIE member (Società Italiana Ematologia)

Research collaborations with Italian and/or foreign institutes

January 2025 to today

Research assignment under the project Mission 4 - Investment 1.4 Strengthening research facilities and creation of "national R&D champions" on some Key Enabling Technologies - National Center for Gene Therapy and Drugs based on RNA Technology project. Scientific managers: Prof.ssa Patrizia Zavattari and Prof.ssa Raffaella Origa.

Agosto 2024 – to today

Head of the Operational Unit in the project financed by the funds of the National Recovery and Resilience Plan (PNRR) Mission 6 - component 2 Investment 2.1 Exploitation and Enhancement of Biomedical Research of the SSN, entitled "Anemia and clonal hematopoiesis in the elderly. Clinical implications", led by the Veneto-AOUI Region of Verona. Scientific Director Prof. Domenico Girelli.

27/08/2020-03/11/2020

Research project entitled "Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma"/ "Semi-ambulatory autotransplant intensification procedure for patients under 66 years old suffering from multiple myeloma." at the Service d'Hématologie Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse France, as part of the Mobility Young Researchers (MGR) programme annuality 2019.

Principal investigator for experimental protocols approved by the ethics committee of Cagliari

23-06-2021- to today

Promoter and Principal investigator of the protocol entitled " Research study on event incidence cardiovascular in polyglobuli: role of hypertension and the renin angiotensin system in the detection of possible predictive and protective factors". Protocol code: CARDIO-POLI." authorized by the Cagliari Ethics Committee Prot PG/2021/9955

22-09-2021 to today

Principal investigator of the protocol entitled "Italian adult immune thrombocytopenia (ITP) registry Codice Protocollo: GIMEMA ITP0918, Codice RSO: ITP0918" authorized by the Cagliari Ethics Committee

22-09-2021 to today

Promoter and Principal investigator of the protocol entitled "Qualità della vita nei pazienti affetti da Porpora Trombotica Trombocitopenica in confronto con una popolazione sana: studio osservazionale monocentrico". Codice protocollo: QoL-PTT" authorized by the Cagliari Ethics Committee Prot. PG/2021/14299

26-01-2022 to today

Principal Investigator of the study promoted by the Istituto Superiore di Sanità entitled "Register for scientific and clinical research on Paroxysmal Nocturnal Hemoglobinuria". Protocol code: RNMR" approved by the ethics committee of Cagliari PROT. PG/2022/1225

30-03-2022 to today

Promoter and principal investigator of the protocol entitled "Studio multicentrico retrospettivo sull'incidenza di dislipidemia ed eventi cardiovascolari in pazienti affetti da leucemia mieloide cronica trattati con inibitori di seconda e terza generazione portatori di trait- talassemico, CTTC" with authorization of the ethics committee of Cagliari (Prot. PG/2022/4996) that sees the collaboration of others Italian Haematological centres. Protocol code: CTTC

27-01-2023 to today

Principal investigator of the protocol entitled "Studio osservazionale su concepimento e gravidanza in pazienti adulti con leucemia mieloide cronica (CML) trattati con inibitori delle tirosin-chinasi" Codice Protocollo: GIMEMA CML1210, Codice RSO: 693" approved by the ethics committee of Cagliari

16-02-2023 to today

Promoter and Principal investigator of the protocol entitled " Prospective monocentric research study: Effect of tyrosine kinase inhibitors on arterial stiffness in patients with myeloid leukemia chronic (CML-PWV)". Protocol code: CML PWV." authorized by the Cagliari Ethics Committee Prot PG/2022/15917

Sub investigator of experimental protocols authorized by the ethics committee of Cagliari

2020-today

Clinical and biological experimental protocol "Studio osservazionale in pazienti con mastocitosi sistemica avanzata trattati con midostaurina in Italia – Studio OVIDIO". Promotore/Sponsor: Novartis

2019-today

Clinical and biological experimental protocol, entitled “Caratteristiche cliniche e laboratoristiche della Policitemia Vera. Codice Protocollo: PV-ARC. Promotore/Sponsor: Unità Operativa di Ematologia-Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi

2019-today

Protocol GIMEMA QoL - MPN0108 “Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative neoplasms (PROPHECY). A GIMEMA observational registry for Italian MPN patients”.

2019-today

Protocol CAMN107AIT15 DANTE “A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year”

2019-today

Protocol GIMEMA INCB-ITMA-CML-401 CML OITI “Observational Study of Iclusig (Ponatinib) Treatment in Patients with Chronic Myeloid Leukemia (CML)in Italy”

2018-2020

Protocol GIMEMA QoL-CML0916: An international field study for the reliability and validity of the Phase IV EORTC Quality of Life module for patients with Chronic Myeloid Leukemia (EORTC QLQ-CML24)

2018-today

Protocol CINC42BIC04. An International Multi-Centric Observational Study on the Use of Ruxolitinib in the Treatment of Patients with Polycythemia Vera resistant or intolerant to hydroxyurea

2018-today

Clinical and biological experimental protocol, approved by the Cagliari Ethics Committee, entitled: Prospective FLOW-cytometry Evaluation of circulating Residual leukemic Stem cells in Chronic Myeloid Leukemia patients during TKI treatment (prospective FLOWERS study). Valutazione prospettica citofluorimetrica delle cellule staminali leucemiche circolanti residue nei pazienti affetti da leucemia mieloide cronica in trattamento con inibitori delle tirosinochinasi (FLOWERS)-Codice identificativo: AIRC IG 20133. Sponsor: Università di Siena

2017-today

Protocol SUSTRENIM. Remissione sostenuta senza trattamento nella leucemia mieloide cronica BCR-ABL+: uno studio prospettico che confronta Nilotinib versus Imatinib con passaggio a Nilotinib in assenza di risposta ottimale”

2015-2017

Protocol AID MORE “Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses”- Prot. AIL 0115 –

2016- today

GIMEMA National Registry for Chronic Myeloid Leukemia

2014-2020

Protocol AMN107AIC05. A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID. Sponsor: Novartis.

2014-today

Protocol QoL-CML0713. Mid to Long-term Quality of Life Effects Of imatiNIB versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS). Sponsor: GIMEMA

2013-2015

Protocol CAMN107CIC03. An observational, open-label, multi-center, prospective follow-up study of patients with chronic phase CML treated with nilotinib in the ENEST1st study. Sponsor Novartis.

Management or involvement in editorial committees of magazines, publishing houses, encyclopaedias, and recognized prestige publications Treaties

Review for the following international journals:

2020 Scientific Reports, Manuscript ID ccabf346-0e94-4be1-b70e-63f98ff0e84c

2021 Expert review of hematology, Manuscript EHM-2020-ST-0176

Clinical Practice & Epidemiology in Mental Health, 2023; 19: e174501792301032.

Clinical Practice & Epidemiology in Mental Health, 2023; 19: e174501792212200.

Frontiers Oncology DOI: 10.3389/fonc.2022.841546

Frontiers in Immunology DOI: 10.3389/fimmu.2022.1010270

Co-author in scientific journal: " Progressi in Ematologia" (PISA, Edizione Teseo) con la stesura del capitolo "Ruolo del trapianto allogenico nelle talassemie" , volume. 3, pagine. 29-37, ISSN: 2704-6826

07-06-2022-today

Member of the Editorial Board as Associate Editor in the journal "Journal of public health research" contained in the Open Science platform "Sage".

07-07-2022-today

Review Editor of review "Autoimmune and Autoinflammatory Disorders" contained in Open Science platform "Frontiers Immunology".

Training and research services at public institutions abroad

01/09/2020-03/11/2020

Observer at Service d'Hématologie Institut Universitaire du Cancer Toulouse – Oncopole, Tolosa Francia

01/10/2010 - 30/06/2011

Erasmus studio at Faculté de Médecine de Strasbourg, Francia

01/06/2011 - 30/06/2011

Clinical stage at Service de Chirurgie Vasculaire. Nouvel Hopital Civil Strasbourg. Professeur N. Chackfe

01/05/2011 - 31/05/2011

Clinical stage at Service de Gynécologie-obstétrique CMCO Strasbourg. Professeur L. Nisand

01/04/2011 - 30/04/2011

Stage clinico presso Service de Chirurgie Digestive et Endocrinienne. Nouvel Hopital Civil Strasbourg. Professeur J. Marescaux

07/03/2011 - 18/03/2011

Clinical stage at Service de Radiologie 1 Strasbourg. Professeur F. Veillon

01/01/2011 - 31/01/2011

Clinical stage at Département d'Hématologie et d'Oncologie. Hopital Hautepierre Strasbourg. Professeur R. Herbrecht

01/12/2010 - 31/12/2010

Clinical stage at Service d'Endocrinologie, Diabète et Maladies Métaboliques Pole Nude Strasbourg. Professeur M. Pinget

Presentations during national congresses

- Speaker at the Congress " XI CONGRESSO MEDICINA DELLO SPORT CITTA' DI CABRAS VII MEMORIAL MARCELLO FAINA "ATTIVITA' FISICA + CORRETTA ALIMENTAZIONE UN BINOMIO VINCENTE NELLE DIVERSE ETA' DELLA VITA" con relazione dal titolo Anemia e sport. Corso ECM, Cabras 24-25 Maggio 2019
- Speaker at the Congress "EXPERT MEETING VIRTUALE ZOOM ON ITP: terapie attuali e nuovi scenari" con relazione dal titolo "Esperienze centro specifiche: Sardegna: gestione degli eventi trombotici nelle ITP". Corso ECM, ONLINE 18 Settembre 2020
- Speaker at the Congress "WORKSHOP EDUCAZIONALE "ON WEB" UPDATE SULLA NMP Ph neg. E LMC" con relazione dal titolo "La terapia con TKI nei pazienti con comorbidità cardiovascolare", congresso patrocinato SIE. Corso ECM, ONLINE 06 e 20 Luglio 2021
- Speaker at the Congress "Evento in modalità webinar PV e ITP strategie di comunicazione efficace per migliorare la qualità della vita del paziente" con relazione dal titolo "Confronto e condivisione di esperienze cliniche". Corso ECM, ONLINE 29 Ottobre e 05 Novembre 2021
- Speaker at the Congress "Evento in modalità webinar PV e ITP strategie di comunicazione efficace per migliorare la qualità della vita del paziente" con relazione dal titolo "Inquadramento della Patologia PV". Corso ECM, ONLINE 29 Ottobre e 05 Novembre 2021
- Speaker at the Congress "Inclusion, I TKI nell'approccio terapeutico alla LMC" , sessione 2 : il ruolo del ponatinib in II linea, con una relazione dal titolo " l'aggiustamento della Dose". Corso ECM, Cagliari 04 Marzo 2022
- Lesson in the Master of High Training and Qualification in Palliative Care of II level, University of Cagliari within the scope of MODULE 7 -With report entitled "LE CURE PALLIATIVE NEL PAZIENTE ONCOLOGICO TERMINALE: Tumori di origine ematologica in fase avanzata di malattia: ruolo palliativo delle terapie oncologiche specifiche nel controllo dei sintomi e nel miglioramento della qualità di vita". ONLINE 11-03-2022
- Speaker at the Congress "Ematologia in Sardegna. V INCONTRO. ATTUALITÀ IN MEDICINA TRASFUSIONALE, EMATOLOGIA CLINICA E TALASSEMIE" sessione n 2 "malattie rare" con relazione dal titolo " Malattia di Gaucher". Corso ECM, Bosa 20-21 Maggio 2022
- Speaker at the Congress " XIII CONGRESSO MEDICINA DELLO SPORT CITTA' DI CABRAS VIII MEMORIAL MARCELLO FAINA "ATTIVITA' FISICA + CORRETTA ALIMENTAZIONE UN BINOMIO VINCENTE NELLE DIVERSE ETA' DELLA VITA?" con una relazione dal titolo "Anemia e sport". Corso ECM, Cabras 27-28 Maggio 2022
- Speaker at the Congress " La multidisciplinarietà nella diagnostica ematopatologica" , sottoseSSIONE "LE NEOPLASIE MIELOPROLIFERATIVE E LE MASTOCITOSI" con relazione dal titolo " Linee terapeutiche nelle neoplasie mieloproliferative croniche". Corso ECM, Cagliari 09-10 giugno 22
- Speaker at the Congress "Next in MPNs work", sessione WORKSHOP SULLE MALATTIE MIELOPROLIFERATIVE PH+ E PH-" con relazione dal titolo " WORKSHOP on CML: come conciliare l'obiettivo terapeutico con la gestione delle comorbidità". Corso ECM, Torino 17-18 Giugno 2022
- Speaker at the Congress " Primo congresso di Onco-nefrologia in Sardegna" sessione danno renale in corso di patologie Ematologiche con relazione dal titolo " Danno renale in corso di trapianto di cellule staminali ematopoietiche". Corso ECM, Cagliari 14-15 Luglio 2022
- Speaker at the Congress: " Corso ibrido Mielofibrosi 2022" promosso da Accademia Nazionale

di Medicina, con relazione dal titolo " L'importanza del team multidisciplinare, discussione di situazioni cliniche didattiche". Corso ECM, Roma 30 Settembre 2022

- Scientific director of the conference " HIKE TOGETHER FOR PV: ematologo e trasfusionista insieme per l'ottimale management del paziente PV Focus on Sardegna" focalizzato sul ruolo di collaborazione tra ematologo e trasfusionista nella gestione ottimale dei pazienti affetti da Policitemia Vera. Corso ECM, 28 October 13 December 2022

- Speaker at the Congress: "ITP Camp 4.0", responsabile scientifico Federico Chiurazzi con una relazione dal titolo " ITP e COVID 19: dall'immunità adattativa al management dell'ITP in era pandemica. Caso Clinico ". Corso ECM, Sorrento 04-05 Novembre 2022

- Speaker at the Congress: "HIKE TOGETHER FOR PV: ematologo e trasfusionista insieme per l'ottimale management del paziente PV Focus on Sardegna", sessione " Ematologo e trasfusionista insieme per l'ottimale management del paziente PV. Dalle Linee guida alla gestione nella pratica quotidiana" con relazione dal titolo " il punto di vista dell'ematologo". Corso ECM, Modalità mista Oristano-ONLINE 28 Ottobre 13 Dicembre 2022

- Lesson in the Master of Advanced Training and Qualification in Thalassemia Management and Level II haemoglobinopathies, Università degli Studi di Cagliari, Con relazione dal titolo "L'esame emocromocitometrico nella normalità e nella patologia: l'adulto". ONLINE 02-12-2022

- Speaker at the Congress: "Nuovi orizzonti nella diagnostica citofluorimetrica in ematologia", con relazione dal titolo " Emoglobinuria parossistica notturna: il punto di vista clinico". Corso ECM, Cagliari 24-25 marzo 2023

- Scientific director of the conference "BIOLOGY OF PLASMA CELLS DYSCRASIAS: FROM BENCH TO BEDSIDE" tenutosi a Cagliari il 21 Aprile 2023.

- Speaker at the Patients-Doctors seminar "Leucemia Mieloide Cronica", Organizzato dall'associazione AIL Con il patrocinio di GIMEMA, con relazione dal titolo " Leucemia mieloide cronica e gravidanza". Cagliari 17 Giugno 2023

- Speaker at the Congress: "New Vision, miglioramento della qualità della vita: ottimizzazione della terapia e della relazione medico-paziente", con relazione dal titolo " ITP e Qualità della vita: quale importanza, quali evidenze". Corso ECM, Firenze_ ONLINE 13 Luglio 2023/11 Luglio 2023/31/10/2023

- Speaker at the Congress: " Tavola rotonda Ematologica Sarda: Stato dell'arte e direzioni future " , sottosezione "Il percorso terapeutico del paziente con LMC" con relazione dal titolo " L'approccio terapeutico al paziente con LMC Resistente e Intollerante ai TKI di 2a generazione". Corso ECM, Cagliari 14 Settembre 2023

- Participation as a teacher in the company training course organized by SERVIZIO SANITARIO REGIONE AUTONOMA DELLA SARDEGNA AZIENDA REGIONALE DELLA SALUTE, dal titolo : "Morfologia delle cellule del sangue: dal normale al patologico". Corso ECM dal 21/09/2023 al 14/12/2023

- Speaker at the Congress: "La nuova classificazione WHO 2022: cosa cambia nelle prospettive diagnostico-terapeutiche delle malattie mieloidi" con relazione dal titolo " Crisi blastiche nelle sindromi mieloproliferative: quale il nuovo approccio terapeutico?". Corso ECM, Cagliari 30 Settembre 2023

- Speaker at the Congress: " Second International "Michele Bacarani" Conference CML and Ph negative Myeloproliferative Disorders", con relazione dal titolo " Is the survival reached for all CML patients- YES". Brescia 22/03/2024

Papers published in indexed and impact factor international journals

- Costa, Alessandro, Abruzzese, Elisabetta, Latagliata, Roberto, Mulas, Olga, Carmosino, Ida, Scalzulli, Emilia, Bisegna, Maria Laura, Ielo, Claudia, Martelli, Maurizio, Caocci, Giovanni, Breccia, Massimo (2024). Safety and Efficacy of TKIs in very Elderly Patients (≥ 75 Years) with Chronic Myeloid Leukemia. *JOURNAL OF CLINICAL MEDICINE*, vol. 13, 273, ISSN: 2077-0383, doi:10.3390/jcm13010273
- Bernardi, Simona, Mulas, Olga, Mutti, Silvia, Costa, Alessandro, Russo, Domenico, La Nasa, Giorgio (2024). Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules. *FRONTIERS IN ONCOLOGY*, vol. 13, ISSN: 2234-943X, doi: 10.3389/fonc.2023.1239042
- Mulas, Olga, Abruzzese, Elisabetta, Luciano, Luigiana, Iurlo, Alessandra, Attolico, Immacolata, Castagnetti, Fausto, Galimberti, Sara, Bonifacio, Massimiliano, Annunziata, Mario, Gozzini, Antonella, O [...] timates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib. *ANNALS OF HEMATOLOGY*, vol. 103, ISSN: 0939-5555, doi: 10.1007/s00277-023-05556-0
- F. Sancassiani, O. Mulas, C. Madeddu, E. Massa, G. La Nasa, G. Caocci, F. Romano, V. Garau, G. Orru, M. Scartozzi, A. E. Nardi, M. G. Carta (2023). Adherence To Treatment In Patients With Solid And Hematological Cancers. Could Spiritual And Psychological Support Facilitate Optimal Adherence?. *World Cancer Research Journal*, Vol. 10, P. 1-7, Issn: 2372-3416, Doi: 10.32113/Wcrj_202312_2727
- Mulas, Olga, Efficace, Fabio, Orofino, Maria Grazia, Piroddi, Antonio, Piras, Eugenia, Vacca, Adriana, Barella, Susanna, Costa, Alessandro, Giesinger, Johannes M., La Nasa, Giorgio, Caocci, Giovanni (2023). Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation. *JOURNAL OF CLINICAL MEDICINE*, vol. 12, 6047, ISSN: 2077-0383, doi: 10.3390/jcm12186047
- Mulas, Olga, Mola, Brunella, Costa, Alessandro, Pittau, Francesca, Mantovani, Daniela, Dessì, Samuele, Fronteddu, Antonella, La Nasa, Giorgio, Caocci, Giovanni (2023). Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension. *ANNALS OF HEMATOLOGY*, vol. 102, p. 2717-2723, ISSN: 0939-5555, doi: 10.1007/s00277-023-05417-w
- Caocci, Giovanni, Mulas, Olga, Barella, Susanna, Orecchia, Valeria, Mola, Brunella, Costa, Alessandro, Efficace, Fabio, La Nasa, Giorgio (2023). Long- Term Health-Related Quality of Life and Clinical Outcomes in Patients with β - Thalassemia after Splenectomy. *JOURNAL OF CLINICAL MEDICINE*, vol. 12, p. 1-10, ISSN: 2077-0383, doi: 10.3390/jcm12072547
- Caocci, G., Mulas, O., Mantovani, D., Bandinu, N., La Nasa, G. (2023). Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura. *THROMBOSIS RESEARCH*, ISSN: 0049-3848, doi:10.1016/j.thromres.2023.06.018
- Alessandro Costa, Raimondo Pittorru, Giovanni Caocci, Federico Migliore, Francesco Tona, Olga Mulas, Giorgio La Nasa (2023). The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia. *HEMATO*, vol. 4, p. 207-226, ISSN: 2673-6357, doi: 10.3390/hemato4030017
- Tiribelli, Mario, Latagliata, Roberto, Breccia, Massimo, Capodanno, Isabella, Miggiano, Maria Cristina, Cavazzini, Francesco, Bucelli, Cristina, Attolico, Immacolata, Crescenzi, Sabrina Leonetti, Russ [...] tline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. *CANCER*, ISSN: 0008-543X, doi: 10.1002/cncr.34923

- F. Sancassiani, O. Mulas, C. Madeddu, E. Massa, G. La Nasa, G. Caocci, F. Romano, V. Garau, G. Orru, M. Scartozzi, A. E. Nardi, M. G. Carta (2023). Low Adherence To Therapy And Co-Morbid Depressive Episodes Are Independent Determinants Of Early Death In People With Cancer. *World Cancer Research Journal*, Vol. 10, P. 1-8, Issn: 2372-3416, Doi: 10.32113/Wcrj_202312_2707
- Sicuranza, Anna, Ferrigno, Ilaria, Abruzzese, Elisabetta, Iurlo, Alessandra, Galimberti, Sara, Gozzini, Antonella, Luciano, Luigiana, Stagno, Fabio, Russo Rossi, Antonella, Sgherza, Nicola, Cattaneo, [...] ng Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). *FRONTIERS IN ONCOLOGY*, vol. 12, p. 1-9, ISSN: 2234-943X, doi:10.3389/fonc.2022.835563
- Barabino, L, Galitzia, A, Murru, R, Caocci, G, Targhetta, C, Greco, M, Angioni, G, Mulas, O, Vacca, A, Piras, E, Frau, V, Costa, A, La Nasa, G (2022). Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation. *EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES*, vol. 26, p. 8984-8989, ISSN: 2284-0729, doi: 10.26355/eurrev_202212_30572
- Mulas, Olga, Mola, Brunella, Madeddu, Clelia, Caocci, Giovanni, Macciò, Antonio, La Nasa, Giorgio (2022). Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. *DIAGNOSTICS*, vol. 12, ISSN: 2075-4418, doi: 10.3390/diagnostics12102493
- Mulas, Olga, Caocci, Giovanni, Efficace, Fabio, Piras, Eugenia, Targhetta, Clara, Frau, Veronica, Barella, Susanna, Piroddi, Antonio, Orofino, Maria Grazia, Vacca, Adriana, La Nasa, Giorgio (2022). Long-term health-related quality of life in patients with β -thalassemia after unrelated hematopoietic stem cell transplantation. *BONE MARROW TRANSPLANTATION*, ISSN: 0268-3369, doi: 10.1038/s41409-022-01823-2
- Madeddu, Clelia, Sanna, Elisabetta, Nemolato, Sonia, Mulas, Olga, Oppi, Sara, Scartozzi, Mario, La Nasa, Giorgio, Maccio, Antonio (2022). Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report. *DIAGNOSTICS*, vol. 12, ISSN: 2075-4418, doi: 10.3390/diagnostics12081910
- Galitzia, Andrea, Barabino, Luca, Murru, Roberta, Caocci, Giovanni, Greco, Marianna, Angioni, Giancarlo, Mulas, Olga, Oppi, Sara, Massidda, Stefania, Costa, Alessandro, La Nasa, Giorgio (2022). Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine. *VACCINES*, vol. 10, ISSN: 2076-393X, doi: 10.3390/vaccines10071162
- Houshmand, Mohammad, Vitale, Nicoletta, Orso, Francesca, Cignetti, Alessandro, Molineris, Ivan, Gaidano, Valentina, Sainas, Stefano, Giorgis, Marta, Boschi, Donatella, Fava, Carmen, Passoni, Alice, Ga [...] useppe (2022). Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. *CELL DEATH & DISEASE*, vol. 13, 576, ISSN: 2041-4889, doi: 10.1038/s41419-022-05028-9
- Mulas O., Mola B., Caocci G., La Nasa G. (2022). Conditioning Regimens in Patients with β -Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review. *JOURNAL OF CLINICAL MEDICINE*, vol. 11, 907, ISSN: 2077-0383, doi: 10.3390/jcm11040907
- Sicuranza, Anna, Ferrigno, Ilaria, Abruzzese, Elisabetta, Iurlo, Alessandra, Galimberti, Sara, Gozzini, Antonella, Luciano, Luigiana, Stagno, Fabio, Russo Rossi, Antonella, Sgherza, Nicola, Cattaneo, [...] ng Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter

- Front-Line TKIs Study (KIARO Study). *FRONTIERS IN ONCOLOGY*, vol. 12, p. 1-9, ISSN: 2234-943X, doi: 10.3389/fonc.2022.835563
- Caocci, Giovanni, Efficace, Fabio, Mulas, Olga, Cottone, Francesco, Maxia, Alessia, Costa, Alessandro, Simula, Maria Pina, Usala, Emilio, La Nasa, Giorgio (2022). Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy. *ANNALS OF HEMATOLOGY*, vol. 101, p. 749-754, ISSN: 0939-5555, doi: 10.1007/s00277-021-04750-2
 - Caocci, Giovanni, Mulas, Olga, Mantovani, Daniela, Costa, Alessandro, Galizia, Andrea, Barabino, Luca, Greco, Marianna, Murru, Roberta, La Nasa, Giorgio (2022). Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. *ANNALS OF HEMATOLOGY*, vol. 101, p. 929-931, ISSN: 0939-5555, doi: 10.1007/s00277-021-04613-w
 - Houshmand, Mohammad, Vitale, Nicoletta, Orso, Francesca, Cignetti, Alessandro, Molineris, Ivan, Gaidano, Valentina, Sainas, Stefano, Giorgis, Marta, Boschi, Donatella, Fava, Carmen, Iurlo, Alessandra, [...] ogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia. *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*, vol. 22 Suppl 2, p. S288-S289, ISSN: 2152-2669, doi: 10.1016/S2152-2650(22)01366-0
 - Specchia, Giordina, Pregno, Patrizia, Breccia, Massimo, Castagnetti, Fausto, Monagheddu, Chiara, Bonifacio, Massimiliano, Tiribelli, Mario, Stagno, Fabio, Caocci, Giovanni, Martino, Bruno, Luciano, Lu [...] all Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. *FRONTIERS IN ONCOLOGY*, vol. 11, 739171, ISSN: 2234-943X, doi: 10.3389/fonc.2021.739171
 - Caocci, Giovanni, Mulas, Olga, Capodanno, Isabella, Bonifacio, Massimiliano, Annunziata, Mario, Galimberti, Sara, Luciano, Luigiana, Tiribelli, Mario, Martino, Bruno, Castagnetti, Fausto, Binotto, Gia [...] levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. *ANNALS OF HEMATOLOGY*, vol. 100, p. 2005-2014, ISSN: 0939-5555, doi: 10.1007/s00277-020-04392-w
 - Rossella Rodia, Fabiana Pani, Giovanni Caocci, Giorgio La Nasa, Maria Pina Simula, Olga Mulas, Fernanda Velluzzi, Andrea Loviselli, Stefano Mariotti, Francesco Boi (2021). Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors. *JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION*, p. 1-10, ISSN: 1720-8386, doi: 10.1007/s40618-021-01613-5
 - Sancassiani, Federica, Massa, Elena, Pibia, Carla, Perda, Giulia, Boe, Laura, Fantozzi, Elena, Cossu, Giulia, Caocci, Giovanni, Mulas, Olga, Morelli, Emanuela, Lindert, Jutta, Lai, Eleonora, Nardi, An [...] epressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. *JOURNAL OF PUBLIC HEALTH RESEARCH*, vol. 10, 2247, ISSN: 2279-9028, doi: 10.4081/jphr.2021.2247
 - Mulas, Olga, Caocci, Giovanni, Dessi, Daniela, Mantovani, Daniela, Moi, Giulia, Cabras, Maria Giuseppina, La Nasa, Giorgio (2021). Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. *ACTA HAEMATOLOGICA*, vol. 144, p. 322-326, ISSN: 0001-5792, doi: 10.1159/000509596
 - Mulas, Olga, Caocci, Giovanni, Mola, Brunella, La Nasa, Giorgio (2021). Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. *FRONTIERS IN PHARMACOLOGY*, vol. 12, 674748, ISSN: 1663-9812, doi: 10.3389/fphar.2021.674748

- Giesinger, Johannes M., La Nasa, Giorgio, Sparano, Francesco, Angermeyer, Matthias, Morelli, Emanuela, Mulas, Olga, Efficace, Fabio, Caocci, Giovanni (2021). Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials. *CLINICAL PRACTICE AND EPIDEMIOLOGY IN MENTAL HEALTH*, vol. 17, p. 307-314, ISSN: 1745-0179, doi: 10.2174/1745017902117010307
- Morelli, Emanuela, Mulas, Olga, Caocci, Giovanni (2021). Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome. *CLINICAL PRACTICE AND EPIDEMIOLOGY IN MENTAL HEALTH*, vol. 17, p. 264-270, ISSN: 1745-0179, doi: 10.2174/1745017902117010264
- Tiribelli, Mario, Capodanno, Isabella, Miggiano, Maria Cristina, Bucelli, Cristina, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Scalzulli, Emilia, Bernardelli, Andrea, Luciano, L [...] rst Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. *BLOOD*, vol. 138, p. 1487, ISSN: 0006-4971, doi: 10.1182/blood-2021-149780
- Caocci, Giovanni, Mulas, Olga, Mantovani, Daniela, Costa, Alessandro, Galizia, Andrea, Barabino, Luca, Greco, Marianna, Murru, Roberta, La Nasa, Giorgio (2021). Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?. *BLOOD*, vol. 138, p. 2573, ISSN: 0006-4971, doi: 10.1182/blood-2021-146381
- Caocci, Giovanni, Mulas, Olga, Annunziata, Mario, Luciano, Luigiana, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Orlandi, Ester Maria, Albano, Francesco, Galimberti, Sara, Iurlo, Alessandra, Pregn [...] d leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 301, p. 163-166, ISSN: 0167-5273, doi: 10.1016/j.ijcard.2019.10.036
- Caocci, Giovanni, Mulas, Olga, Capodanno, Isabella, Abruzzese, Elisabetta, Iurlo, Alessandra, Luciano, Luigiana, Albano, Francesco, Annunziata, Mario, Tiribelli, Mario, Bonifacio, Massimiliano, Galimb [...] terial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. *BLOOD CANCER JOURNAL*, vol. 10, ISSN: 2044-5385, doi: 10.1038/s41408-020-0333-2
- Mulas, Olga, Caocci, Giovanni, Stagno, Fabio, Bonifacio, Massimiliano, Annunziata, Mario, Luciano, Luigiana, Orlandi, Ester Maria, Abruzzese, Elisabetta, Sgherza, Nicola, Martino, Bruno, Albano, Franc [...] rtension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. *ANNALS OF HEMATOLOGY*, vol. 99, p. 1525-1530, ISSN: 0939-5555, doi: 10.1007/s00277-020-04102-6
- Caocci, Giovanni, Deidda, Martino, Noto, Antonio, Greco, Marianna, Simula, Maria Pina, Mulas, Olga, Cocco, Daniele, Fattuoni, Claudia, Mercurio, Giuseppe, La Nasa, Giorgio, Cadeddu Dessalvi, Christian (2020). Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. *JOURNAL OF CLINICAL MEDICINE*, vol. 9, ISSN: 2077-0383, doi: 10.3390/jcm9041180
- Caocci, Giovanni, Simula, Maria Pina, Ghiani, Silvia, Mulas, Olga, Mainas, Giorgia, Atzeni, Sandra, Pettinau, Martina, Usala, Emilio, La Nasa, Giorgio (2020). Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting. *INTERNATIONAL JOURNAL OF HEMATOLOGY*, vol. 111, p. 614-618, ISSN: 0925-5710, doi: 10.1007/s12185-020-02861-6
- Mulas, Olga, Caocci, Giovanni, Annunziata, Mario, Martino, Bruno, Luciano, Luigiana, Castagnetti, Fausto, Pregn, Patrizia, Galimberti, Sara, Albano, Francesco, Orlandi, Ester Maria, Sgherza, Nicola, [...]). Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. *HEMATOLOGICAL ONCOLOGY*, vol. 38, p. 607-610, ISSN: 0278-0232, doi: 10.1002/hon.2765

- Cazaubiel, Titouan, Mulas, Olga, Montes, Lydia, Schavgoulidze, Anaïs, Avet-Loiseau, Hervé, Corre, Jill, Perrot, Aurore (2020). Risk and Response-Adapted Treatment in Multiple Myeloma. *CANCERS*, vol. 12, p. 1-16, ISSN: 2072-6694, doi: 10.3390/cancers12123497
- Caocci, Giovanni, Mulas, Olga, Abruzzese, Elisabetta, Luciano, Luigiana, Iurlo, Alessandra, Attolico, Immacolata, Castagnetti, Fausto, Galimberti, Sara, Sgherza, Nicola, Bonifacio, Massimiliano, Annun [...] ted with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. *HEMATOLOGICAL ONCOLOGY*, vol. 37, p. 296-302, ISSN: 0278-0232, doi: 10.1002/hon.2606
- Caocci, Giovanni, Mulas, Olga, Abruzzese, Elisabetta, Iurlo, Alessandra, Annunziata, Mario, Orlandi, Ester Maria, Galimberti, Sara, Binotto, Gianni, Sgherza, Nicola, Luciano, Luigia, Martino, Bruno, R [...] iovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. *ANNALS OF HEMATOLOGY*, vol. 98, p. 1885-1890, ISSN: 0939-5555, doi: 10.1007/s00277-019-03705-y
- Caocci, Giovanni, Mulas, Olga, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Galimberti, Sara, Orlandi, Ester Maria, Iurlo, Alessandra, Annunziata, Mario, Luciano, Luigiana, Castagnetti, Fausto, Goz [...] second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 288, p. 124-127, ISSN: 0167-5273, doi: 10.1016/j.ijcard.2019.04.051
- Giovanni Caocci, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, MULAS, OLGA, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercurio, Giorgio La Nasa (2019). Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. *BLOOD*, vol. 134, p. 4144, ISSN: 1528-0020, doi: 10.1182/blood-2019-124323
- Caocci, Giovanni, MULAS, Olga, Annunziata, Mario, Luciano, Luigiana, Bonifacio, Massimiliano, Orlandi, Ester Maria, Pregno, Patrizia, Galimberti, Sara, Russo Rossi, Antonella, Abruzzese, Elisabetta, I [...] ond-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. *AMERICAN JOURNAL OF HEMATOLOGY*, ISSN: 0361-8609, doi: 10.1002/ajh.25102
- Bocchia, Monica, Sicuranza, Anna, Abruzzese, Elisabetta, Iurlo, Alessandra, Sirianni, Santina, Gozzini, Antonella, Galimberti, Sara, Aprile, Lara, Martino, Bruno, Pregno, Patrizia, Sorà, Federica, Alu [...] blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. *FRONTIERS IN ONCOLOGY*, vol. 8, ISSN: 2234- 943X, doi: 10.3389/fonc.2018.00194
- CAOCCI, GIOVANNI, Greco, Marianna, Arras, Marcella, Cusano, Roberto, ORRU, SANDRO, Martino, Bruno, Abruzzese, Elisabetta, Galimberti, Sara, Mulas, Olga, Trucas, Marcello, Littera, Roberto, Lai, Sara, CARCASSI, CARLO, LA NASA, GIORGIO (2017). HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. *LEUKEMIA RESEARCH*, vol. 61, p. 1-5, ISSN: 0145-2126, doi: 10.1016/j.leukres.2017.08.005
- CAOCCI, GIOVANNI, Martino, Bruno, GRECO, MARIANNA, Abruzzese, Elisabetta, Trawinska, Malgorzata Monika, Lai, Sara, RAGATZU, PAOLA, Galimberti, Sara, Baratè, Claudia, Mulas, Olga, Labate, Claudia, Littera, Roberto, CARCASSI, CARLO, Passerini, Carlo Gambacorti, LA NASA, GIORGIO (2015). Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. *EXPERIMENTAL HEMATOLOGY*, vol. 43, p. 1015-1018, ISSN: 0301-472X, doi: 10.1016/j.exphem.2015.08.004
- LA NASA, GIORGIO, CAOCCI, GIOVANNI, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, ORRU, SANDRO, Orrù N, FLORIS, ANDREA, CARCASSI, CARLO (2013). Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.

EXPERIMENTAL HEMATOLOGY, vol. 41, p. 424-431, ISSN: 0301-472X, doi:
10.1016/j.exphem.2013.01.008

- CAOCCI, GIOVANNI, LA NASA, GIORGIO, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, ORRU, SANDRO, Orrù N, Usai M, Floris A, CARCASSI, CARLO (2013). Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. HAEMATOLOGICA, vol. 98, p. 303, ISSN: 0390-6078

Chapters of Italian books or magazines

Mulas O, Caocci G, La Nasa G, Ruolo del trapianto allogenico nelle talassemie. pp.29-37. In Progressi in ematologia (PISA) - ISSN:2704-6826 vol. 1 anno 2020

language skills

French: excellent knowledge of written and spoken language, B2 Delf, C2 TCF certifications

English : moderate knowledge of written and spoken language, B2

I consent to the processing of my personal data pursuant to D.lgs. 196 of 30 June 2003. The statements contained herein are made pursuant to art. 46 and 47 of D.P.R. 445/2000.

Read, confirmed and signed.

Cagliari, li 06/04/2025

THE APPLICANT

Olga Mulas